{"id":634375,"date":"2023-01-17T16:42:02","date_gmt":"2023-01-17T16:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634375"},"modified":"2023-01-17T16:42:02","modified_gmt":"2023-01-17T16:42:02","slug":"invasive-pneumococcal-disease-market-to-grow-substantially-during-the-forecast-period-201932-delveinsight-key-companies-vaxcyte-vax24-pfizer-pf06482077-merck-afinivax-eubiologics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/invasive-pneumococcal-disease-market-to-grow-substantially-during-the-forecast-period-201932-delveinsight-key-companies-vaxcyte-vax24-pfizer-pf06482077-merck-afinivax-eubiologics_634375.html","title":{"rendered":"Invasive Pneumococcal Disease Market to Grow Substantially During the Forecast Period (2019-32) – DelveInsight | Key Companies – Vaxcyte (VAX-24), Pfizer (PF-06482077), Merck, Afinivax, Eubiologics"},"content":{"rendered":"
\n
\"Invasive<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Invasive Pneumococcal Disease Market is anticipated to grow in the coming years owing to the entry of broad-coverage vaccines in a market with a huge at-risk population and extensive research and development activities of pharmaceutical companies.<\/div>\n

DelveInsight’s “Invasive Pneumococcal Disease Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Invasive Pneumococcal Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Invasive Pneumococcal Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Invasive<\/p>\n

Invasive Pneumococcal Disease: An Overview<\/strong><\/p>\n

According to European Centre for Disease Prevention and Control (ECDC)<\/strong>, pneumococcal diseases are symptomatic infections caused by the bacterium Streptococcus pneumoniae (S. pneumoniae), commonly referred to as pneumococci. The term Invasive Pneumococcal Disease is used for more severe and invasive pneumococcal infections, such as bacteremia, sepsis, meningitis, and osteomyelitis.<\/p>\n

Improved diagnostic techniques and more efficacious treatments may help reduce the burden of pneumococcal disease, but preventive measures, such as influenza and pneumococcal vaccination, should be promoted to avoid preventable diseases, particularly in the elderly.<\/p>\n

Treatment includes antibiotic therapy for symptomatic patients. Symptomatic treatment for patients in most geographies is by “Infectious Disease – Clinical Practice Guidelines,” prescribed by respective health organizations like CDC(US), NICE(UK), ECDPC(EU), etc.,<\/em><\/p>\n

Invasive Pneumococcal Disease Market Key Facts<\/strong><\/p>\n